134 related articles for article (PubMed ID: 12680143)
1. In vitro responses of ovarian cancers to platinums and taxanes.
Kornblith P; Wells A; Gabrin MJ; Piwowar J; Chattopadhyay A; George LD; Ochs RL; Burholt D
Anticancer Res; 2003; 23(1B):543-8. PubMed ID: 12680143
[TBL] [Abstract][Full Text] [Related]
2. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
3. Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients.
Agiostratidou G; Sgouros I; Galani E; Voulgari A; Chondrogianni N; Samantas E; Dimopoulos MA; Skarlos D; Gonos ES
Anticancer Res; 2001; 21(1A):455-9. PubMed ID: 11299779
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
5. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer.
Herzog TJ; Krivak TC; Fader AN; Coleman RL
Am J Obstet Gynecol; 2010 Jul; 203(1):68.e1-6. PubMed ID: 20227055
[TBL] [Abstract][Full Text] [Related]
7. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
Matsuo K; Eno ML; Im DD; Rosenshein NB
Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
[TBL] [Abstract][Full Text] [Related]
9. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
10. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
11. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
12. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy for recurrent ovarian cancer].
Nishimura H; Imamura K; Chang C
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
19. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
